Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImaRx Therapeutics has been awarded a $1.1 million grant from the National Heart Lung and Blood Institute, a division of the National Institutes of Health, for the development of targeted "nanobubbles" that can be used in conjunction with ultrasound for NanoInvasive treatment of vascular clots.
Subscribe to our email newsletter
Clinical studies of ImaRx’s lead product candidate, SonoLysis, have demonstrated the power of nanobubbles in conjunction with ultrasound to break up blood clots. Under the NHLBI grant award, the company will develop new, highly selective nanobubbles for targeted blood clot treatment in patients suffering from heart attack.
“Selectivity through targeted delivery is the key to the development of more effective and safer alternatives to current treatment paradigms,” said Dr Terry Matsunaga, vice president research, ImaRx.
“Because they are designed to find areas of thrombosis, where they are activated by ultrasound waves to mechanically break apart clots, our targeted nanobubbles in conjunction with ultrasound are a potentially safer option for MI (myocardial infarction) treatment than standard of care treatments such as lytic drugs and emergency thrombectomies,” added Dr Matsunaga.